Amwell's Strategic Inducement Grant to Dan Zamansky
Amwell (NYSE: AMWL), a leading provider of technology-enabled care, has recently taken a significant step towards enhancing its leadership team. The company announced the grant of restricted stock units (RSUs) covering 220,844 shares of its Class A common stock to Dan Zamansky as part of his induction as the Chief Product and Technology Officer. This strategic decision marks a critical investment in the company's vision for future growth.
Details of the Restricted Stock Units Grant
The RSUs granted to Zamansky are structured to vest over a four-year period. Specifically, 25% of the RSUs will vest on the six-month anniversary of the grant date, with the remaining 75% vesting in equal increments every three months thereafter. Such a structure ensures that Zamansky is incentivized to remain with Amwell, aligning his interests with the long-term goals of the company.
Vesting Conditions and Employment Terms
Continuity in Zamansky's role is vital, as the RSUs are conditioned on his continued employment with the company. If circumstances arise where Zamansky's employment ends without cause or he departs for good reason, his RSU grant will partially vest. This policy not only shows Amwell's commitment to its employees but also ensures that leadership remains robust during transitions.
Termination Scenarios and Control Changes
In the event of an involuntary termination, particularly within a critical window surrounding a change in control, the RSUs will fully vest. This measure is designed to protect key personnel and maintain stability within leadership amid potential corporate shifts.
About Amwell and Its Evolving Mission
Amwell has a longstanding reputation for offering comprehensive, technology-driven healthcare solutions. Their platform provides healthcare systems and payers with effective tools to enhance patient access to care. With a focus on affordability and convenience, Amwell is positioned as an integral player in the evolving landscape of healthcare.
Innovative Care Solutions at Scale
Throughout its nearly two-decade history, Amwell has successfully partnered with a multitude of sophisticated healthcare organizations across the globe. This collaboration enables the delivery of diversified clinical programs through a unified platform, resulting in seamless patient experiences.
Commitment to Future-Ready Solutions
As the demand for online healthcare solutions rises, Amwell continues to innovate. Their technology not only empowers patients but also enhances the effectiveness of clinical programs, ensuring that Amwell remains a formidable force in health technology.
Frequently Asked Questions
What is the purpose of Amwell's inducement grant?
The inducement grant aims to attract Dan Zamansky to the role of Chief Product and Technology Officer, aligning his financial incentives with the company’s long-term objectives.
How do the RSUs vest for Zamansky?
The RSUs vest over a four-year period, with 25% vesting after six months and the rest in equal increments every three months thereafter.
What happens if Zamansky leaves the company?
If Zamansky leaves without cause or departs for good reason, a portion of his RSUs will vest, providing security for his transition.
Why is vesting tied to employment?
This structure ensures that leadership remains committed to Amwell's vision and incentivizes long-term engagement within the organization.
How does Amwell support healthcare providers?
Amwell provides a comprehensive platform that enhances patient access to innovative and effective care solutions, supporting healthcare providers and their patients alike.
